Compare CVS Health Corp (CVS) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Tapestry, Inc. — how do they compare? CVS Health Corp trades at $104.32 (market cap $135.48B), while Tapestry, Inc. trades at $135.74 (market cap $27.35B). The key difference: CVS Health Corp is far larger — about 5× Tapestry, Inc.'s market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | TPR | |
|---|---|---|
Market Cap | $135.48B | $27.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $106.18 | $160.49 |
52-Week Low | $58.75 | $95.69 |
Enterprise Value | $202.02B | $30.20B |
Dividend Yield | 2.51% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
TPR is trading at $136.13, down 3.27% today, with a bearish technical signal despite strong analyst support. The company shows impressive profitability with 76.18% gross margins and 55.74% ROE, though recent earnings declined significantly from $816M in 2024 to $183M in 2025. Recent quarters have consistently beaten EPS expectations, with Q1 2026 reporting $1.66 versus $1.30 expected.
The stock presents a compelling growth opportunity with 75.6% analyst buy ratings and a $184.14 consensus target, representing 35% upside. However, elevated P/E of 41.5 and recent net income contraction warrant caution. Key risks include high debt levels and competitive pressures in the luxury retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
